GPR84,
a Gi protein-coupled receptor that is activated
by medium-chain (hydroxy)fatty acids, appears to play an important
role in inflammation, immunity, and cancer. Recently, 6-octylaminouracil
(4) has been reported to act as an agonist at GPR84.
Here, we describe the synthesis of 69 derivatives and analogs of 4, 66 of which represent new compounds. They were evaluated
in (a) cyclic adenosine monophosphate accumulation and (b) β-arrestin
assays in human GPR84-expressing cells. Potent nonbiased as well as
G protein-biased agonists were developed, e.g., 6-hexylamino-2,4(1H,3H)-pyrimidinedione (20,
PSB-1584, EC50 5.0 nM (a), 3.2 nM (b), bias factor: 0)
and 6-((p-chloro- and p-bromo-phenylethyl)amino)-2,4(1H,3H)-pyrimidinedione (47,
PSB-16434, EC50 7.1 nM (a), 520 nM (b), bias factor: 1.9
= 79-fold Gi pathway-selective; 48, PSB-17365,
EC50 2.5 nM (a), 100 nM (b), bias factor 1.3 = 20-fold
selective), which were selective versus other free fatty acid-activated
receptors. Compounds 20 and 48 were found
to be metabolically stable upon incubation with human liver microsomes.
A pharmacophore model was created on the basis of structurally diverse
lipidlike GPR84 agonists.